bsi-045b
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2021 (NCT05114889)
Timeline
Indications
Studied for
Mechanism of action
- Thymic stromal lymphopoietinINHIBITOR
TSLP inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314979 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05932654 | Phase 2 | Jul 31, 2023 | Biosion, Inc. |
| NCT05114889 | Phase 1 | Oct 15, 2021 | Biosion, Inc., Scientia Clinical Research Limited Sydney, Southern Star Research Pty Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biosion, Inc. | For profit | 2 | 2 | 2 | 2021 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2021 |
| Southern Star Research Pty Ltd. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1